Skip to content

HALP as a Novel Score for Prediction of Mortality and re_bleeding in Upper GIT Bleeding

Moglobin, Albumin, Lymphocyte and Platelet Score as a Novel Predictor of Mortality and Re-bleeding in Patients With Upper Gastrointestinal Bleeding

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07114042
Enrollment
100
Registered
2025-08-11
Start date
2025-08-08
Completion date
2026-02-28
Last updated
2025-08-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Upper Gastrointestinal Bleeding

Brief summary

Evaluation of the prognostic utility of the HALP score in patients with upper gastrointestinal bleeding, particularly in predicting re\_bleeding risk and mortality in internal medicine department in Sohag University Hospitals.

Detailed description

Study for evaluation of the utility of hemoglobin, Albumin, Lymphocyte and Platelat score in prediction of mortality and re\_bleeding in patient with upper gastrointestinal bleeding, Patients will be included if they were initially admitted to the emergency department, had a confirmed diagnosis of upper gastrointestinal bleeding via endoscopy, and were 18 years of age or older.

Interventions

DIAGNOSTIC_TESTUpper endoscopy

Prediction of upper gastrointestinal r\_bleeding and mortality

Sponsors

Sohag University
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum

Inclusion criteria

* Patients will be included if they were initially admitted to the emergency department, had a confirmed diagnosis of upper gastrointestinal bleeding via endoscopy, and were 18 years of age or older.

Exclusion criteria

* Incomplete clinical data. * Lack of laboratory results obtained at emergency department admission necessary for the calculation of HALP score; albumin, hemoglobin (HGB), platelets (PLT), or international normalized ratio (INR). * Pregnancy * Patients with missing data on clinical outcomes

Design outcomes

Primary

MeasureTime frame
Mortality6 months
Incidence of Re_bleeding6 months

Countries

Egypt

Contacts

Primary ContactReham R Baeoumy, Master
reham.refaat@med.edu.eg0106 3367488

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026